Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OVR106
MIFTS: 47

Ovarian Clear Cell Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Ovarian Clear Cell Carcinoma

About this section

MalaCards integrated aliases for Ovarian Clear Cell Carcinoma:

Name: Ovarian Clear Cell Carcinoma 12 15
Clear-Cell Ovarian Carcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Endocrine diseases Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050934
Sources

Summaries for Ovarian Clear Cell Carcinoma

About this section
Disease Ontology : 12 An ovarian carcinoma that has material basis in cells with clear cytoplasm and glycogen secreting hob nail cells.

MalaCards based summary : Ovarian Clear Cell Carcinoma, also known as clear-cell ovarian carcinoma, is related to ovarian cancer 1 and endometrioid ovary carcinoma. An important gene associated with Ovarian Clear Cell Carcinoma is ARID1A (AT-Rich Interaction Domain 1A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Downstream signaling events of B Cell Receptor (BCR). The drugs Sunitinib and Pembrolizumab have been mentioned in the context of this disorder. Affiliated tissues include ovary, lung and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 76 Clear cell ovarian carcinoma is one of several subtypes of ovarian carcinoma. The two types of ovarian... more...

Sources

Related Diseases for Ovarian Clear Cell Carcinoma

About this section

Diseases in the Ovarian Clear Cell Carcinoma family:

Ovarian Small Cell Carcinoma

Diseases related to Ovarian Clear Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
# Related Disease Score Top Affiliating Genes
1 ovarian cancer 1 30.4 ARID1A HNF1B KRAS KRT7 PIK3CA TP53
2 endometrioid ovary carcinoma 30.2 ARID1A PPP2R1A
3 clear cell adenofibroma 30.1 ARID1A KRT7 PIK3CA
4 ovarian cancer 30.0 CD44 HNF1B KRAS KRT7 PIK3CA PTEN
5 renal cell carcinoma, nonpapillary 29.9 CD44 HNF1B KRT7 NAPSA
6 adenocarcinoma 29.5 KRAS NAPSA PIK3CA PTEN TP53
7 endometriosis 10.6
8 endocarditis 10.3
9 adult hepatocellular carcinoma 10.2 PIK3CA TP53
10 spiradenoma 10.2 KRT7 TP53
11 breast squamous cell carcinoma 10.2 PIK3CA TP53
12 vulvar intraepithelial neoplasia 10.2 KRT7 TP53
13 papillary adenoma 10.2 KRT7 NAPSA
14 ovarian clear cell adenocarcinoma 10.2 ARID1A HNF1B PIK3CA
15 thymus adenocarcinoma 10.2 KRT7 NAPSA
16 anal squamous cell carcinoma 10.2 PIK3CA TP53
17 bladder carcinoma in situ 10.2 KRT7 TP53
18 vulvar disease 10.2 KRT7 TP53
19 papillary serous adenocarcinoma 10.2 KRT7 TP53
20 clear cell adenocarcinoma 10.2 ARID1A HNF1B KRT7
21 marantic endocarditis 10.2
22 cystadenoma 10.2
23 apocrine adenoma 10.2 KRAS PIK3CA
24 lichen sclerosus 10.2 CD44 TP53
25 krukenberg carcinoma 10.1 HNF1B KRT7 NAPSA
26 aggressive digital papillary adenocarcinoma 10.1 KRAS PIK3CA
27 glycogen-rich clear cell breast carcinoma 10.1 KRT7 TP53
28 malignant spiradenoma 10.1 KRT7 PIK3CA TP53
29 thyroid hurthle cell adenoma 10.1 PIK3CA PTEN
30 hyperplastic polyposis syndrome 10.1 KRAS TP53
31 hidradenoma 10.1 KRT7 PIK3CA
32 mutyh-associated polyposis 10.1 KRAS TP53
33 lung adenoid cystic carcinoma 10.1 KRAS PIK3CA
34 duodenum adenocarcinoma 10.1 KRAS KRT7
35 gastric adenosquamous carcinoma 10.1 CD44 TP53
36 uterine corpus serous adenocarcinoma 10.1 PIK3CA PPP2R1A TP53
37 appendix disease 10.1 KRAS KRT7
38 uterine corpus cancer 10.1 PIK3CA PPP2R1A TP53
39 prostate squamous cell carcinoma 10.1 KRT7 PPP2R1A TP53
40 omodysplasia 10.1 CD44 GPC3
41 synchronous bilateral breast carcinoma 10.1 PTEN TP53
42 endometriosis of ovary 10.1
43 hypoxia 10.1
44 mixed cell type cancer 10.1 KRT7 PPP2R1A TP53
45 anal canal adenocarcinoma 10.1 KRAS KRT7
46 rare adenocarcinoma of the breast 10.1 KRAS PIK3CA TP53
47 seminal vesicle tumor 10.1 GPC3 KRT7
48 mature teratoma 10.1 KRAS TP53
49 corneal abscess 10.1 KRT7 PTEN
50 embryoma 10.1 GPC3 HNF1B

Graphical network of the top 20 diseases related to Ovarian Clear Cell Carcinoma:



Diseases related to Ovarian Clear Cell Carcinoma
Sources

Symptoms & Phenotypes for Ovarian Clear Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 46)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.63 FXYD2 ZNF217
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 10.63 FXYD2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.63 FXYD2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.63 KRAS
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 10.63 HNF1B
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.63 KRAS
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.63 ZNF217
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-150 10.63 HNF1B
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-155 10.63 ZNF217
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.63 KRAS
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-167 10.63 HNF1B
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.63 FXYD2 ZNF217
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 10.63 HNF1B
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10.63 ZNF217
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.63 KRAS
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 10.63 NAPSA
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.63 KRAS ZNF217
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 10.63 KRAS FXYD2
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.63 NAPSA
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.63 KRAS HNF1B
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.63 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.63 KRAS
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.63 NAPSA
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.63 KRAS NAPSA PTEN
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 10.63 ARID1B HNF1B
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 10.63 FXYD2
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.63 NAPSA ARID1B FXYD2 HNF1B ZNF217
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.63 PTEN ZNF217
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.63 FXYD2
30 Decreased viability in esophageal squamous lineage GR00235-A 9.76 ARID1A CD44 HNF1B KRAS KRT7 PIK3CA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.64 ARID1B
32 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.64 ARID1B HNF1B PIK3CA
33 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.64 ARID1B PIK3CA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.64 ARID1B PIK3CA
35 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.64 HNF1B PIK3CA
36 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.64 HNF1B
37 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.64 PIK3CA
38 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.64 HNF1B
39 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.64 ARID1B
40 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.64 PIK3CA
41 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.64 HNF1B
42 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.64 HNF1B PIK3CA
43 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.64 HNF1B
44 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.64 HNF1B
45 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.64 HNF1B
46 Increased cell death HMECs cells GR00103-A-0 9.35 PIK3CA PPP2R1A PTEN TP53 ZNF217

MGI Mouse Phenotypes related to Ovarian Clear Cell Carcinoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 ARID1A ARID1B CD44 GPC3 HNF1B KRAS
2 growth/size/body region MP:0005378 10.18 ARID1A ARID1B CD44 GPC3 HNF1B KRAS
3 cardiovascular system MP:0005385 10.13 ARID1A ARID1B CD44 GPC3 KRAS PIK3CA
4 mortality/aging MP:0010768 10.1 ARID1A ARID1B CD44 GPC3 HNF1B KRAS
5 immune system MP:0005387 10.09 ARID1A ARID1B CD44 GPC3 HNF1B KRAS
6 embryo MP:0005380 10.05 ARID1A GPC3 HNF1B KRAS PIK3CA PTEN
7 endocrine/exocrine gland MP:0005379 10.04 ARID1A CD44 HNF1B KRAS PIK3CA PTEN
8 muscle MP:0005369 9.97 ARID1A ARID1B CD44 HNF1B KRAS PIK3CA
9 neoplasm MP:0002006 9.87 ARID1A CD44 KRAS PIK3CA PPP2R1A PTEN
10 renal/urinary system MP:0005367 9.76 ARID1B CD44 GPC3 HNF1B KRAS KRT7
11 pigmentation MP:0001186 9.65 CD44 GPC3 KRAS PTEN TP53
12 reproductive system MP:0005389 9.5 ARID1A CD44 GPC3 KRAS PIK3CA PTEN
13 skeleton MP:0005390 9.17 ARID1A CD44 GPC3 KRAS PIK3CA PTEN
Sources

Drugs & Therapeutics for Ovarian Clear Cell Carcinoma

About this section

Drugs for Ovarian Clear Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
2
Pembrolizumab Approved Phase 2 1374853-91-4
3
Nintedanib Approved Phase 2 656247-17-5 56843413
4
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
5
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
6
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
7
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
8
Bevacizumab Approved, Investigational Phase 2 216974-75-3
9
Nivolumab Approved Phase 2 946414-94-4
10
Doxil Approved June 1999 Phase 2 31703
11 Angiogenesis Inhibitors Phase 2
12 Angiogenesis Modulating Agents Phase 2
13 Topoisomerase Inhibitors Phase 2
14 Antibiotics, Antitubercular Phase 2
15 Anti-Bacterial Agents Phase 2
16 Antineoplastic Agents, Phytogenic Phase 2
17 topoisomerase I inhibitors Phase 2
18 Antimitotic Agents Phase 2
19 Albumin-Bound Paclitaxel Phase 2
20 tyrosine Phase 2
21 Immunologic Factors Phase 2
22 Immunoglobulins Phase 2,Phase 1
23 Antibodies, Monoclonal Phase 2
24 Antibodies Phase 2,Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Study of ENMD-2076 in Ovarian Clear Cell Cancers Completed NCT01914510 Phase 2 ENMD-2076
2 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
3 Pembrolizumab and Epacadostat in Treating Participants With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma Recruiting NCT03602586 Phase 2 Epacadostat
4 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
5 A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
6 BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting NCT03355976 Phase 2 Nivolumab;Ipilimumab
7 A Study of PLX2853 in Advanced Malignancies. Recruiting NCT03297424 Phase 1, Phase 2 PLX2853
8 A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Terminated NCT02837991 Phase 1 CDX-014

Search NIH Clinical Center for Ovarian Clear Cell Carcinoma

Sources

Genetic Tests for Ovarian Clear Cell Carcinoma

About this section
Sources

Anatomical Context for Ovarian Clear Cell Carcinoma

About this section

MalaCards organs/tissues related to Ovarian Clear Cell Carcinoma:

41
Ovary, Lung, Bone, Colon, Prostate, Thyroid, Appendix
Sources

Publications for Ovarian Clear Cell Carcinoma

About this section

Articles related to Ovarian Clear Cell Carcinoma:

(show top 50) (show all 274)
# Title Authors Year
1
Successful treatment of platinum refractory ovarian clear cell carcinoma with secondary cytoreductive surgery and implantable transponder placement to facilitate targeted volumetric arc radiation therapy. ( 30555884 )
2019
2
Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes. ( 29751993 )
2018
3
Ovarian Clear Cell Carcinoma: From Morphology to Molecular Biology. ( 29629954 )
2018
4
Prognostic Value of Serum CA19-9 and Perioperative CA-125 Levels in Ovarian Clear Cell Carcinoma. ( 29781825 )
2018
5
Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma. ( 29400012 )
2018
6
The HNF-1I^-USP28-Claspin pathway upregulates DNA damage-induced Chk1 activation in ovarian clear cell carcinoma. ( 29707125 )
2018
7
Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing. ( 29044863 )
2018
8
The possible existence of occult metastasis in patients with ovarian clear-cell carcinoma who underwent complete resection without any residual tumours. ( 29464073 )
2018
9
Benign mesothelial nodules reflux within acquired cutaneous lymphangiectasia associated with huge ovarian clear cell carcinoma. ( 29222819 )
2018
10
Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma. ( 29725737 )
2018
11
Uncommon Human Telomerase Reverse Transcriptase Promoter Mutations Are Associated With Poor Survival in Ovarian Clear Cell Carcinoma. ( 29474637 )
2018
12
Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma. ( 29675093 )
2018
13
Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute. ( 29941051 )
2018
14
PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma. ( 29632642 )
2018
15
Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma. ( 29963273 )
2018
16
Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma. ( 29679177 )
2018
17
Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma. ( 29663364 )
2018
18
Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma? ( 29383437 )
2018
19
ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma. ( 29890703 )
2018
20
Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. ( 29233531 )
2018
21
Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma. ( 29685880 )
2018
22
Somatic copy number alterations have prognostic impact in patients with ovarian clear cell carcinoma. ( 29749539 )
2018
23
Imaging in gynecological disease: clinical and ultrasound characteristics of ovarian clear cell carcinoma. ( 29978567 )
2018
24
Occult ovarian clear-cell carcinoma diagnosed as primary adenocarcinoma of the lung: A case report of a diagnostic pitfall for clinicians and pathologists. ( 30386720 )
2018
25
A case of ovarian clear cell carcinoma arising from ovarian mature cystic teratoma. ( 30165878 )
2018
26
Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1). ( 29986747 )
2018
27
HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation. ( 29989198 )
2018
28
ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies. ( 30025943 )
2018
29
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. ( 30108107 )
2018
30
Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor. ( 30109783 )
2018
31
Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. ( 30217369 )
2018
32
Ovarian Clear Cell Carcinoma Detected During Long-Term Management of Endometriotic Cysts in Young Patients: Possible Heterogeneity of this Tumor. ( 30423566 )
2018
33
Identification of potential key genes associated with ovarian clear cell carcinoma. ( 30519094 )
2018
34
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). ( 29921512 )
2018
35
Napsin-A, a Possible Diagnostic Marker for Differentiating Clear Cell Ovarian Carcinoma From Other High-grade Ovarian Carcinomas. ( 28362708 )
2018
36
KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clear‑cell carcinoma cells. ( 29749467 )
2018
37
MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma. ( 28161486 )
2017
38
Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis. ( 27939411 )
2017
39
Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma. ( 28930811 )
2017
40
Safety of fertility-sparing surgery for stage I ovarian clear cell carcinoma. ( 29027405 )
2017
41
UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan. ( 28173214 )
2017
42
Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression. ( 27873496 )
2017
43
Identification of LEFTY as a molecular marker for ovarian clear cell carcinoma. ( 28969018 )
2017
44
Low uptake of fluorodeoxyglucose in positron emission tomography/computed tomography in ovarian clear cell carcinoma may reflect glutaminolysis of its cancer stem cell-like properties. ( 28112360 )
2017
45
Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. ( 28187748 )
2017
46
The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma<i>In Vitro</i>and<i>In Vivo</i>. ( 29061793 )
2017
47
Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma? ( 28758377 )
2017
48
Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma inA vitro. ( 28259988 )
2017
49
Role of endometriosis as a prognostic factor for post-progression survival in ovarian clear cell carcinoma. ( 29285368 )
2017
50
Ovarian clear cell carcinoma with plasma cell-rich inflammatory stroma: Cytological Findings of a Case. ( 27718331 )
2017
Sources

Variations for Ovarian Clear Cell Carcinoma

About this section

Cosmic variations for Ovarian Clear Cell Carcinoma:

9 (show top 50) (show all 230)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6947228 ZFHX3 ovary,NS,carcinoma,clear cell carcinoma c.3472G>A p.G1158R 16:72829836-72829836 9
2 COSM11606 TP53 ovary,NS,carcinoma,clear cell carcinoma c.31G>C p.E11Q 17:7676564-7676564 9
3 COSM11123 TP53 ovary,NS,carcinoma,clear cell carcinoma c.838A>G p.R280G 17:7673782-7673782 9
4 COSM10663 TP53 ovary,NS,carcinoma,clear cell carcinoma c.916C>T p.R306* 17:7673704-7673704 9
5 COSM10667 TP53 ovary,NS,carcinoma,clear cell carcinoma c.646G>A p.V216M 17:7674885-7674885 9
6 COSM44923 TP53 ovary,NS,carcinoma,clear cell carcinoma c.565G>C p.A189P 17:7674966-7674966 9
7 COSM43896 TP53 ovary,NS,carcinoma,clear cell carcinoma c.818G>C p.R273P 17:7673802-7673802 9
8 COSM10725 TP53 ovary,NS,carcinoma,clear cell carcinoma c.701A>G p.Y234C 17:7674262-7674262 9
9 COSM10648 TP53 ovary,NS,carcinoma,clear cell carcinoma c.524G>A p.R175H 17:7675088-7675088 9
10 COSM43697 TP53 ovary,NS,carcinoma,clear cell carcinoma c.832C>A p.P278T 17:7673788-7673788 9
11 COSM10738 TP53 ovary,NS,carcinoma,clear cell carcinoma c.542G>A p.R181H 17:7675070-7675070 9
12 COSM10704 TP53 ovary,NS,carcinoma,clear cell carcinoma c.844C>T p.R282W 17:7673776-7673776 9
13 COSM6071317 TBX3 ovary,NS,carcinoma,clear cell carcinoma c.307C>A p.P103T 12:114682894-114682894 9
14 COSM20625 STK3 ovary,NS,carcinoma,clear cell carcinoma c.178G>C p.V60L 8:98767301-98767301 9
15 COSM21355 STK11 ovary,NS,carcinoma,clear cell carcinoma c.842C>T p.P281L 19:1221320-1221320 9
16 COSM6966368 STAT3 ovary,NS,carcinoma,clear cell carcinoma c.271C>T p.Q91* 17:42346571-42346571 9
17 COSM6926931 STAT3 ovary,NS,carcinoma,clear cell carcinoma c.1907C>T p.S636F 17:42322476-42322476 9
18 COSM6974933 STAT3 ovary,NS,carcinoma,clear cell carcinoma c.1238T>G p.L413R 17:42329453-42329453 9
19 COSM980818 SPOP ovary,NS,carcinoma,clear cell carcinoma c.148G>A p.E50K 17:49621998-49621998 9
20 COSM6904351 SPOP ovary,NS,carcinoma,clear cell carcinoma c.235G>A p.E79K 17:49619351-49619351 9
21 COSM88679 SPOP ovary,NS,carcinoma,clear cell carcinoma c.139G>A p.E47K 17:49622007-49622007 9
22 COSM6973364 SOX9 ovary,NS,carcinoma,clear cell carcinoma c.92C>G p.A31G 17:72121483-72121483 9
23 COSM6919565 SOX9 ovary,NS,carcinoma,clear cell carcinoma c.604G>A p.A202T 17:72122891-72122891 9
24 COSM6019342 SMARCA4 ovary,NS,carcinoma,clear cell carcinoma c.467G>T p.G156V 19:10986300-10986300 9
25 COSM255312 SMARCA4 ovary,NS,carcinoma,clear cell carcinoma c.3727C>T p.R1243W 19:11033470-11033470 9
26 COSM6926933 SMARCA4 ovary,NS,carcinoma,clear cell carcinoma c.3564C>A p.D1188E 19:11033307-11033307 9
27 COSM14146 SMAD4 ovary,NS,carcinoma,clear cell carcinoma c.1135G>A p.A379T 18:51065602-51065602 9
28 COSM6947226 SMAD3 ovary,NS,carcinoma,clear cell carcinoma c.1136G>T p.G379V 15:67187491-67187491 9
29 COSM132950 SF3B1 ovary,NS,carcinoma,clear cell carcinoma c.1996A>C p.K666Q 2:197402637-197402637 9
30 COSM6931475 RPTOR ovary,NS,carcinoma,clear cell carcinoma c.3365C>T p.T1122M 17:80949542-80949542 9
31 COSM6917539 RNF43 ovary,NS,carcinoma,clear cell carcinoma c.702G>C p.Q234H 17:58360930-58360930 9
32 COSM6981024 RICTOR ovary,NS,carcinoma,clear cell carcinoma c.449T>C p.V150A 5:38996826-38996826 9
33 COSM241316 PTPRT ovary,NS,carcinoma,clear cell carcinoma c.2162G>A p.R721H 20:42282503-42282503 9
34 COSM6923181 PTPRD ovary,NS,carcinoma,clear cell carcinoma c.5279C>A p.A1760E 9:8339022-8339022 9
35 COSM5219 PTEN ovary,NS,carcinoma,clear cell carcinoma c.388C>G p.R130G 10:87933147-87933147 9
36 COSM5036 PTEN ovary,NS,carcinoma,clear cell carcinoma c.202T>C p.Y68H 10:87925550-87925550 9
37 COSM5089 PTEN ovary,NS,carcinoma,clear cell carcinoma c.517C>T p.R173C 10:87952142-87952142 9
38 COSM23650 PTEN ovary,NS,carcinoma,clear cell carcinoma c.728T>C p.F243S 10:87957946-87957946 9
39 COSM6019341 PTCH1 ovary,NS,carcinoma,clear cell carcinoma c.3073C>T p.R1025C 9:95458108-95458108 9
40 COSM51211 PPP2R1A ovary,NS,carcinoma,clear cell carcinoma c.547C>T p.R183W 19:52212729-52212729 9
41 COSM51253 PPP2R1A ovary,NS,carcinoma,clear cell carcinoma c.548G>A p.R183Q 19:52212730-52212730 9
42 COSM76040 PPP2R1A ovary,NS,carcinoma,clear cell carcinoma c.771G>T p.W257C 19:52213074-52213074 9
43 COSM86040 PPP2R1A ovary,NS,carcinoma,clear cell carcinoma c.772C>T p.R258C 19:52213075-52213075 9
44 COSM51210 PPP2R1A ovary,NS,carcinoma,clear cell carcinoma c.547C>G p.R183G 19:52212729-52212729 9
45 COSM51212 PPP2R1A ovary,NS,carcinoma,clear cell carcinoma c.544C>T p.R182W 19:52212726-52212726 9
46 COSM6917537 POLE ovary,NS,carcinoma,clear cell carcinoma c.1124G>A p.R375Q 12:132675500-132675500 9
47 COSM6919564 PLK2 ovary,NS,carcinoma,clear cell carcinoma c.344A>T p.H115L 5:58459019-58459019 9
48 COSM6981028 PLCG2 ovary,NS,carcinoma,clear cell carcinoma c.2200C>T p.P734S 16:81919629-81919629 9
49 COSM775 PIK3CA ovary,NS,carcinoma,clear cell carcinoma c.3140A>G p.H1047R 3:179234297-179234297 9
50 COSM12458 PIK3CA ovary,NS,carcinoma,clear cell carcinoma c.1634A>C p.E545A 3:179218304-179218304 9

Copy number variations for Ovarian Clear Cell Carcinoma from CNVD:

7 (show top 50) (show all 427)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13831 1 1 88452 Loss Ovarian clear cell carcinoma
2 14094 1 103933871 104104913 Loss Ovarian clear cell carcinoma
3 14228 1 105814888 105835737 Loss Ovarian clear cell carcinoma
4 14767 1 110029012 110047636 Gain Ovarian clear cell carcinoma
5 14768 1 110029027 110046508 Loss Ovarian clear cell carcinoma
6 15067 1 112489835 112507466 Gain Ovarian clear cell carcinoma
7 15068 1 112491838 112507466 Loss Ovarian clear cell carcinoma
8 18079 1 143856437 146851948 Gain Ovarian clear cell carcinoma
9 18686 1 147137550 147788457 Gain Ovarian clear cell carcinoma
10 18898 1 147703455 147884062 Loss Ovarian clear cell carcinoma
11 18938 1 147964875 159663147 Gain Ovarian clear cell carcinoma
12 18939 1 147964875 159663147 Gain Ovarian clear cell carcinoma
13 19585 1 150821801 150857105 Loss Ovarian clear cell carcinoma
14 19705 1 151026303 151040528 Loss Ovarian clear cell carcinoma
15 21673 1 16022491 16026775 Gain Ovarian clear cell carcinoma
16 21674 1 16024203 16038247 Loss Ovarian clear cell carcinoma
17 22558 1 167482724 167509012 Loss Ovarian clear cell carcinoma
18 22559 1 167482724 167521488 Gain Ovarian clear cell carcinoma
19 22780 1 16889448 16921459 Gain Ovarian clear cell carcinoma
20 24231 1 177344731 177346824 Loss Ovarian clear cell carcinoma
21 24465 1 180956979 181720785 Gain Ovarian clear cell carcinoma
22 25838 1 194981485 195068682 Gain Ovarian clear cell carcinoma
23 25839 1 194981485 195083340 Loss Ovarian clear cell carcinoma
24 26133 1 197378133 197380848 Loss Ovarian clear cell carcinoma
25 26790 1 202780704 202781223 Loss Ovarian clear cell carcinoma
26 27522 1 209500000 222100000 Amplification CENPF Ovarian clear cell carcinoma
27 28170 1 219471 557615 Gain Ovarian clear cell carcinoma
28 28576 1 223563323 234670833 Gain Ovarian clear cell carcinoma
29 29195 1 228800000 234600000 Amplification TARBP1 Ovarian clear cell carcinoma
30 29315 1 230223390 230231832 Loss Ovarian clear cell carcinoma
31 29845 1 236917532 236921700 Loss Ovarian clear cell carcinoma
32 29954 1 238458352 238460749 Loss Ovarian clear cell carcinoma
33 30919 1 246707804 246877268 Gain Ovarian clear cell carcinoma
34 30947 1 246804059 246863823 Loss Ovarian clear cell carcinoma
35 31115 1 25455917 25517758 Gain Ovarian clear cell carcinoma
36 31116 1 25455917 25534075 Loss Ovarian clear cell carcinoma
37 32697 1 38901189 38907774 Gain Ovarian clear cell carcinoma
38 36176 1 72522942 72600553 Loss Ovarian clear cell carcinoma
39 36192 1 72535947 72584491 Gain Ovarian clear cell carcinoma
40 37128 1 85775755 85782373 Loss Ovarian clear cell carcinoma
41 37531 1 92007142 92023072 Loss Ovarian clear cell carcinoma
42 39168 10 11150202 11151804 Loss Ovarian clear cell carcinoma
43 41309 10 15959139 15974926 Loss Ovarian clear cell carcinoma
44 41503 10 19683194 19835050 Loss Ovarian clear cell carcinoma
45 41826 10 24415258 24418944 Gain Ovarian clear cell carcinoma
46 41827 10 24415258 24420691 Loss Ovarian clear cell carcinoma
47 42276 10 31286505 31291815 Loss Ovarian clear cell carcinoma
48 42716 10 3813637 3819468 Gain Ovarian clear cell carcinoma
49 42973 10 4276898 4287271 Gain Ovarian clear cell carcinoma
50 43007 10 42910287 42910797 Gain Ovarian clear cell carcinoma
Sources

Expression for Ovarian Clear Cell Carcinoma

About this section
Search GEO for disease gene expression data for Ovarian Clear Cell Carcinoma.
Sources

Pathways for Ovarian Clear Cell Carcinoma

About this section

Pathways related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 37
Show member pathways
 12.83 KRAS PIK3CA PPP2R1A PTEN TP53
2
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.58 KRAS PIK3CA PPP2R1A PTEN TP53
3
Development HGF signaling pathway 22
Show member pathways
 12.55 KRAS PIK3CA PTEN TP53
4
Gastric cancer 37
Show member pathways
 12.47 ARID1A ARID1B KRAS PIK3CA PTEN TP53
5
MicroRNAs in cancer 37
12.31 CD44 KRAS PIK3CA PTEN TP53
6
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.26 CD44 GPC3 KRAS PIK3CA
7
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.23 GPC3 KRAS PIK3CA PTEN TP53
8
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.06 KRAS PIK3CA PTEN TP53
9
mTOR Pathway 72
Show member pathways
 12.03 KRAS PIK3CA TP53
10
Cellular senescence (KEGG) 37
12.03 KRAS PIK3CA PTEN TP53
11
Integrated Breast Cancer Pathway 1
12 KRAS PTEN TP53
12
Development EGFR signaling via small GTPases 22
Show member pathways
 11.99 KRAS PIK3CA PTEN
13
AKT Signaling Pathway 67
11.99 KRAS PIK3CA PTEN TP53
14
Longevity regulating pathway 37
Show member pathways
 11.98 KRAS PIK3CA TP53
15
Proteoglycans in cancer 37
11.96 CD44 GPC3 KRAS PIK3CA TP53
16
FoxO signaling pathway 37
Show member pathways
 11.93 KRAS PIK3CA PTEN
17
Hepatitis C 37
11.91 KRAS PIK3CA PPP2R1A TP53
18
Autophagy - animal 37
11.89 KRAS PIK3CA PTEN
19
Glioblastoma Multiforme 64
11.83 KRAS PTEN TP53
20
Thyroid hormone signaling pathway 37
11.82 FXYD2 KRAS PIK3CA TP53
21
Senescence and Autophagy in Cancer 1
11.8 CD44 PTEN TP53
22
DNA Damage Response (only ATM dependent) 1
11.77 KRAS PIK3CA PTEN TP53
23
Small cell lung cancer 37
11.73 PIK3CA PTEN TP53
24
Copper homeostasis 1
11.47 PIK3CA PTEN TP53
25
Pathways Affected in Adenoid Cystic Carcinoma 1
11.28 ARID1A PIK3CA PTEN TP53
26
Aldosterone-regulated sodium reabsorption 37
11.25 FXYD2 KRAS PIK3CA
27
PI3K-AKT-mTOR signaling pathway and therapeutic opportunities 1
11.13 KRAS PIK3CA PTEN
28
Sphingolipid signaling pathway 37
11.09 KRAS PIK3CA PPP2R1A PTEN TP53
29
Central carbon metabolism in cancer 37
11.07 KRAS PIK3CA PTEN TP53
Sources

GO Terms for Ovarian Clear Cell Carcinoma

About this section

Cellular components related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 SWI/SNF complex GO:0016514 9.16 ARID1A ARID1B
2 nBAF complex GO:0071565 8.96 ARID1A ARID1B
3 SWI/SNF superfamily-type complex GO:0070603 8.62 ARID1A ARID1B

Biological processes related to Ovarian Clear Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.62 HNF1B KRAS PTEN TP53
2 liver development GO:0001889 9.33 HNF1B KRAS PIK3CA
3 regulation of synaptic transmission, GABAergic GO:0032228 9.26 KRAS PTEN
4 chromatin-mediated maintenance of transcription GO:0048096 8.96 ARID1A ARID1B
5 neuron-neuron synaptic transmission GO:0007270 8.62 ARID1B PTEN
Sources

Sources for Ovarian Clear Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....